Strengthening Real‐World Evidence on Question Not Answered by Randomized Trials: A Trial Calibration Approach-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Strengthening Real‐World Evidence on Question Not Answered by Randomized Trials: A Trial Calibration Approach

Published:2024-09 Issue:9 Volume:33 Page:
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiology and Drug

Author:

Kirchgesner Julien¹²^ORCID,Wang Shirley V.¹^ORCID,Schneeweiss Sebastian¹^ORCID

Affiliation:

1. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA

2. AP‐HP, Hôpital Saint‐Antoine, Department of Gastroenterology Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique Paris France

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.70008

Reference16 articles.

1. US Food and Drug Administration “Framework for FDA's Real‐World Evidence Program ” 2018 https://www.fda.gov/media/120060/download.

2. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

3. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

4. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment

5. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP